Table 6 Concomitant LABA and ICS users stratified by age group, sex, and inhaler type (“Combined Inhalers”, “Separate Inhalers”, “Combinations”) for the year 2008*

0-9

3,262 (76.9%)

1,735 (75.8%)

219 (5.2%)

135 (5.9%)

761 (17.9%)

418 (18.3%)

4,242 (100%)

2,288 (100%)

10-19

9,121 (88.2%)

6,208 (87.9%)

550 (5.3%)

422 (6.0%)

676 (6.5%)

430 (6.1%)

10,347 (100%)

7,060 (100%)

20-29

6,052 (90.9%)

7,208 (89.9%)

436 (6.5%)

525 (6.6%)

172 (2.6%)

281 (3.5%)

6,660 (100%)

8,014 (100%)

30-39

7,053 (88.5%)

9,034 (87.2%)

669 (8.4%)

885 (8.5%)

250 (3.1%)

444 (4.3%)

7,972 (100%)

10,363 (100%)

40-49

10,015 (87.1%)

14,110 (86.0%)

1,102 (9.6%)

1,515 (9.2%)

386 (3.4%)

788 (4.8%)

11,503 (100%)

16,413 (100%)

50-59

8,777 (85.1%)

13,239 (84.8%)

1,120 (10.9%)

1,624 (10.4%)

413 (4.0%)

748 (4.8%)

10,310 (100%)

15,611 (100%)

60-69

10,454 (83.7%)

14,200 (84.1%)

1,545 (12.4%)

1,906 (11.3%)

489 (3.9%)

779 (4.6%)

12,488 (100%)

16,885 (100%)

70-79

9,428 (83.5%)

12,121 (84.5%)

1,368 (12.1%)

1,594 (11.1%)

495 (4.4%)

625 (4.4%)

11,291 (100%)

14,340 (100%)

80-89

3,469 (85.2%)

5,712 (86.1%)

433 (10.6%)

650 (9.8%)

169 (4.2%)

270 (4.1%)

4,071 (100%)

6,632 (100%)

90+

178 (87.3%)

408 (87.7%)

17 (8.3%)

35 (7.5%)

9 (4.4%)

22 (4.7%)

204 (100%)

465 (100%)

Total

67,809 (85.7%)

83,975 (85.6%)

7,459 (9.4%)

9,291 (9.5%)

3,820 (4.8%)

4,805 (4.9%)

79,088 (100%)

98,071 (100%)